View
12
Download
0
Embed Size (px)
Citation preview
What price is right? Pharmaceutical pricing for Canadians.
Carole Watson, Director, Strategic Pricing, Janssen Inc.
GETTING TO ACCESS Innovative approaches to innovative medicines Canadian Organization for Rare Disorders March 29, 2017. Vancouver
GETTING TO ACCESS Innovative approaches to innovative medicines
Canadian Organization for Rare Disorders March 29, 2017. Vancouver
.
Artwork by Sebastian Ferreira Janssen is proud to feature artwork created by people affected
by the illnesses and diseases we are committed to treating and preventing.
GETTING TO ACCESS Innovative approaches to innovative medicines
Canadian Organization for Rare Disorders March 29, 2017. Vancouver
.
Then Now Types of medicines: Large populations + lower cost / patient Small populations + higher cost / patient
Local pricing decisions Globalized pricing frameworks
List Prices HTA, ICERs pCPA: Confidential rebates Private Payer agreements
Wide array of science Targeted science
Innovation threshold lower Higher innovation level required for success
R&D investment – large scale centres R&D investment across the Life Sciences Ecosystem
Randomized Controlled Trials RCTs + Real World Evidence
Stronger economies Prolonged economic slowdown
Younger populations Older populations
Treated in hospitals Treated in the community
Canadian reimbursement environment is still rapidly evolving
Health Canada Patented Medicine Prices Review Board
HTA (CDR, INESSS, pCODR)
Pan Canadian Pharmaceutical Alliance (pCPA)
Private Insurer Assessments
Provincial Payer Listings (PLAs)
“Drugwatch” type programs
Price and value hurdles between innovation and patients in Canada
3/29/17
GETTING TO ACCESS Innovative approaches to innovative medicines
Canadian Organization for Rare Disorders March 29, 2017. Vancouver
.
3/29/17 GETTING TO ACCESS
Innovative approaches to innovative medicines Canadian Organization for Rare Disorders
March 29, 2017. Vancouver .
§ Patients are always at the center
§ Broad understanding of value – to patients, healthcare system, society
§ Access for patients today
§ Incentive for investment in biomedical innovation to transform the lives of patients tomorrow
Medicines are priced to ensure patient access today – and tomorrow
3/29/17
GETTING TO ACCESS Innovative approaches to innovative medicines
Canadian Organization for Rare Disorders March 29, 2017. Vancouver
.
Source:CIHI(NHEX),PMPRBAnnualReport2015,StatisticsCanada.MethodologyinspiredbyBrettSkinner.SpendingonPatentedMedicinesinCanada.CHPI,2016.CalculationsbyInnovativeMedicinesCanada,September2016..*CAGR2005-2014
15%
25%
60%
0
1000
2000
3000
4000
5000
6000
+4.1% CAGR*
Non-Drug Costs: +8.4% CAGR*
PatentedDrugs:+0.8%CAGR*
Healthcare Sustainability: Innovative Drugs and Beyond
$, Per Capita
20%
32%
48%
Non-drug costs
Non-Patented drugs
Patented drugs
GETTING TO ACCESS Innovative approaches to innovative medicines
Canadian Organization for Rare Disorders March 29, 2017. Vancouver
.
Non-PatentedDrugs:+7.6%CAGR*
Total Drug Costs:
All Other Health, Excluding Drugs
Dr. Paul Janssen
“There are still many diseases for which there is no cure, and effective medicines must be found.
Although we have contributed to the solutions for some of these problems, we will continue our research efforts, because so much more needs to be done.”
3/29/17
GETTING TO ACCESS Innovative approaches to innovative medicines
Canadian Organization for Rare Disorders March 29, 2017. Vancouver
.